NCT02380066已完成2 期
Proof Of Concept Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 6
- 主要终点
- The change of total score from baseline in MADRS scale
研究概览
简要总结
The purpose of this study is to determine whether Anyu Peibo Capsule in different doses are effective in the treatment of Depression.
And to explore the preliminary information of safety and efficacy of Anyu Peibo Capsule in the Chinese Patients with Depression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria of DSM-IV-TR, single episode or recurrent episode, not accompanied with psychotic symptoms. Coding of diagnosis included: 296.21 MDD single episode, mild 296.22 MDD single episode, moderate 296.31 MDD recurrent episode, mild 296.32 MDD recurrent episode, moderate
- •The total score of HAMD-17 is ≥18 and ≤24 in both screening visit and baseline visit.
- •The subject understands and consents to takes part in this clinical trials. The subjects should sign informed consent.
排除标准
- •The subject has a significant risk of suicide according to the investigator's opinion or has a score ≥3 on item 3(suicide assessment) of the HAMD or has made a suicide attempt.
- •The subject has a current DSM-Ⅳ-TR axisⅠpsychiatric diagnosis other than depression.
- •When the HAMD17 score of baseline visit compares with the screening visit, the decreasing rate is ≥25%.
- •Any unstable cardiovascular, hepatic, renal, endocrine(thyroid gland dysfunction), blood,or other medical disease.
- •Had a history of seizure disorder,except infantile febrile convulsion.
- •The subject has accepted psychosurgery or electroconvulsive therapy within 3months.
- •With psychotic symptoms.
- •The subject has a history of mania episode, including manic, mixed or rapid cycle attack.
- •The subject has a current diagnosis or history of depression due to any other psychotic disorder or a general medical condition.
- •The subject with refractory depressive disorder,i.e.the patients who used at least two different mechanisms antidepressants with adequate dosage and duration treatment still had no respond.
- •Clinically significant electrocardiographic(ECG) abnormalities or abnormal laboratory values(eg. Hepatic function above 1.5 times of clinical toplimit, renal function or thyroid gland function index above toplimit, routine blood, fasting blood glucose value above or below 1.1 times of the upper limit of normal or in 1.1 times with the clinical significance of abnormality).
- •The subject has a diagnosis of alcohol or other substance abuse or dependence at least 1 years prior to the baseline visit.
- •Known hypersensitivity to Big Leaf Ju, or at least to two kinds of drugs, or serious allergic physique.
- •Women who were pregnant, breast-feeding, or planning to become pregnant during study. Men who have request to fertility during study period. The subject could not take safe and effective birth control measures.
- •The subject could not take medication according to the doctor's advice. i.e. the compliance of the subject is poor.
- •The subject uses antidepressant drug normally before 2 weeks of screening, and stops using psychotropic drug less than 7 half-life period (monoamine oxidase inhibitor more than 2 weeks, fluoxetine more than 1 month).
- •The subject has participated in a drug clinical trial within 1 month before screening.
- •The investigator think the subject is unsuitable to enrol in this clinical trial.
研究组 & 干预措施
Anyu Peibo 0.4g per day
Experimental
Anyu Peibo Capsule, oral, 0.2g twice per day
干预措施: Anyu Peibo (Drug)
Anyu Peibo 0.8g per day
Experimental
Anyu Peibo Capsule, oral, 0.4g twice per day
干预措施: Anyu Peibo (Drug)
Anyu Peibo 1.2g per day
Experimental
Anyu Peibo Capsule, oral, 0.6g twice per day
干预措施: Anyu Peibo (Drug)
Anyu Peibo 1.6g per day
Experimental
Anyu Peibo Capsule, oral, 0.8g twice per day
干预措施: Anyu Peibo (Drug)
Placebo
Placebo Comparator
Placebo,oral, twice per day
干预措施: Anyu Peibo (Drug)
结局指标
主要结局
The change of total score from baseline in MADRS scale
时间窗: 6 weeks
次要结局
- clinical response rate according to MADRS(6 weeks)
- clinical remission rate according to MADRS(6 weeks)
- CGI(CGI-S,CGI-I)(6 weeks)
- decreasing rate from baseline in HAMD scale(6 weeks)
- clinical response rate according to HAMD(6 weeks)
- The change of total score from baseline in HAMD scale(6 weeks)
- clinical remission rate according to HAMD(6 weeks)
- change from baseline in HAMA(6 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
3 期
Comparison of Anyu Peibo With Placebo in Treatment of MDD in ChinaMajor Depressive DisorderNCT04210973Shanghai Mental Health Center266
已完成
2 期
Comparison of Anyu Peibo With Placebo in Treatment of MDD，ⅡbMajor Depressive DisorderNCT03183505Shanghai Mental Health Center172
招募中
4 期
A clinical study to assess the efficacy and safety of Ayurvedic treatment Kneesol oil to compare with Dr Ortho oil and Diclofenac gel in Rheumatoid arthritis patients.CTRI/2023/04/052114Madhusudan Healthcare
Unknown
2 期
Comparison of Yuxintine With Placebo in Treatment of MDDMajor Depressive Disorder (MDD)NCT02395263Shanghai Mental Health Center160
尚未招募
2 期
Ayurvedic treatment of female infertilityCTRI/2021/04/032549Parul Institute Of Ayurved